Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | RECQL | P46063 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340407 | 0.76 | L3MBTL1 (0.46) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL9844222 | 0.73 | MAPT (0.49) | ALDH1A1RECQLCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL27748259 | 0.70 | SMN1; SMN2 (0.49) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL11904827 | 0.70 | CTSB (0.58) | ALDH1A1RECQLL3MBTL1MAPTHPGD | |
| SCHEMBL987193 | 0.69 | CYP2C19 (0.43) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27769560 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL11904840 | 0.69 | CTSB (0.54) | ALDH1A1RECQLL3MBTL1KMT2AMAPT | |
| SCHEMBL17240907 | 0.68 | ALOX5 (0.49) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 | |
| Acetic Acid SCHEMBL30128630 | 0.68 | ALOX5 (0.45) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL12286073 | 0.67 | ALOX5 (0.51) | ALDH1A1RECQLCYP3A4CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180878-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2024-06-06 | — | — | US | claimed |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | MEAD JOHNSON NUTRITION COMPANY (US) | 2018-07-31 | — | — | US | claimed |
| US-20170215464-A1 | NUTRITIONAL COMPOSITIONS CONTAINING DIETARY BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-08-03 | — | — | US | claimed |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-06-08 | — | — | US | claimed |
| US-20170127693-A1 | NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-05-11 | — | — | US | claimed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | claimed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | claimed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | claimed |
| US-20240180878-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2024-06-06 | — | — | US | disclosed |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | MEAD JOHNSON NUTRITION COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170215464-A1 | NUTRITIONAL COMPOSITIONS CONTAINING DIETARY BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-08-03 | — | — | US | disclosed |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-06-08 | — | — | US | disclosed |
| US-20170127693-A1 | NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-05-11 | — | — | US | disclosed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | ALDH1A1 1497/4885RECQL 4788/4885CYP3A4 679/4885 |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | FABP2, LRBA, TSLP | ALDH1A1 3938/4885RECQL 4773/4885CYP3A4 924/4885 |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | FABP2, LRBA, TSLP | ALDH1A1 3938/4885RECQL 4773/4885CYP3A4 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.